|
(b)(4).The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history identified no other similar incidents and/or complaints from this lot.It was reported that the device was prepped inside the anatomy.It should be noted that the percutaneous transluminal angioplasty (pta), armada 14 xt, over the wire (ot), global instructions for use (ifu) specifies: caution: all air must be removed from the balloon and displaced with contrast medium (diluted 1:1 with normal saline) prior to inserting into the body (repeat steps 4a through 4g, if necessary); otherwise, complications may occur.In this case, it is unknown if the ifu violation caused or contributed to the reported complaint.The investigation determined the reported complaints appear to be related to operational context.There is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.
|
|
It was reported that the procedure was to treat a 100% stenosed, heavily calcified, mildly tortuous, chronic totally occluded (cto) lesion in the superficial femoral artery (sfa).The 1.5x20 mm armada 14 percutaneous transluminal angioplasty (pta) catheter was not air aspirated outside the anatomy prior to use in the patient.The device was advanced with resistance noted with the anatomy and was inflated twice to 8 atmospheres (atm).The balloon ruptured and would not inflate a third time.A 1.5x40 mm armada 14 pta catheter was used in replacement.There were no adverse patient effects and there was no clinically significant delay in the procedure.No additional information was provided.
|